BRPI0515494A - uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina - Google Patents

uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina

Info

Publication number
BRPI0515494A
BRPI0515494A BRPI0515494-4A BRPI0515494A BRPI0515494A BR PI0515494 A BRPI0515494 A BR PI0515494A BR PI0515494 A BRPI0515494 A BR PI0515494A BR PI0515494 A BRPI0515494 A BR PI0515494A
Authority
BR
Brazil
Prior art keywords
etval
meala
cyclosporine
treatment
infection
Prior art date
Application number
BRPI0515494-4A
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of BRPI0515494A publication Critical patent/BRPI0515494A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"USO DE ¢D-MEALA! 3-¢ETVAL!4-CICLOSPORINA PARA O TRATAMENTO DE INFECçãO POR HEPATITE C E COMPOSIçãO FARMACêUTICA COMPREENDENDO A REFERIDA ¢D-MEALA!3-¢ETVAL!4-CICLOSPORINA". A presente invenção refere-se ao uso, no tratamento de infecção por HCV, de uma ciclosporina, seja como agentes ativos individuais ou em combinação com um outro agente ativo, dotada de atividade de ligação à ciclofilina aumentada, e, carecendo essencialmente, de atividade imunossupressora.
BRPI0515494-4A 2004-10-01 2005-10-03 uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina BRPI0515494A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number Publication Date
BRPI0515494A true BRPI0515494A (pt) 2008-07-29

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515494-4A BRPI0515494A (pt) 2004-10-01 2005-10-03 uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina

Country Status (29)

Country Link
US (3) US7439227B2 (pt)
EP (1) EP1793844B1 (pt)
JP (1) JP4892486B2 (pt)
KR (1) KR101191833B1 (pt)
CN (1) CN101056648B (pt)
AT (1) ATE490778T1 (pt)
AU (1) AU2005290984B2 (pt)
BR (1) BRPI0515494A (pt)
CA (1) CA2580448C (pt)
CY (1) CY1114594T1 (pt)
DE (1) DE602005025232D1 (pt)
DK (1) DK1793844T3 (pt)
EA (1) EA012650B1 (pt)
ES (1) ES2357587T3 (pt)
GE (1) GEP20104960B (pt)
HR (1) HRP20110169T1 (pt)
IL (1) IL182362A0 (pt)
MA (1) MA28950B1 (pt)
MX (1) MX2007003387A (pt)
NZ (1) NZ554412A (pt)
PL (1) PL1793844T3 (pt)
PT (1) PT1793844E (pt)
RS (1) RS51614B (pt)
SG (1) SG139750A1 (pt)
SI (1) SI1793844T1 (pt)
TN (1) TNSN07084A1 (pt)
UA (1) UA88484C2 (pt)
WO (1) WO2006038088A1 (pt)
ZA (1) ZA200702610B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
CA2587793A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
WO2006071618A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
CA2623898C (en) 2005-10-26 2013-12-24 Astellas Pharma Inc. New cyclic peptide compounds
CA2643680A1 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
ES2396170T3 (es) 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
WO2009042892A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US8501683B2 (en) * 2008-11-06 2013-08-06 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
SG173180A1 (en) 2009-01-30 2011-09-29 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
KR20140035305A (ko) * 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
PL2694087T3 (pl) 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
SG10201602184TA (en) * 2011-04-13 2016-04-28 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
KR20140070565A (ko) 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
SG11201406441RA (en) 2012-05-07 2014-11-27 Novartis Ag Pharmacokinetic modulation with alisporivir
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
SG11201601274QA (en) 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3623378B1 (en) 2017-05-12 2025-07-02 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
PT1091975E (pt) * 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP4892486B2 (ja) 2012-03-07
CN101056648B (zh) 2012-08-15
MX2007003387A (es) 2007-05-23
US7772184B2 (en) 2010-08-10
EA012650B1 (ru) 2009-12-30
EP1793844A1 (en) 2007-06-13
DK1793844T3 (da) 2011-03-21
EP1793844B1 (en) 2010-12-08
JP2008514690A (ja) 2008-05-08
ES2357587T3 (es) 2011-04-27
MA28950B1 (fr) 2007-10-01
HK1104236A1 (en) 2008-01-11
PL1793844T3 (pl) 2011-05-31
ZA200702610B (en) 2008-08-27
ATE490778T1 (de) 2010-12-15
CA2580448C (en) 2012-09-18
TNSN07084A1 (en) 2008-06-02
AU2005290984B2 (en) 2010-09-09
DE602005025232D1 (de) 2011-01-20
SI1793844T1 (sl) 2011-05-31
CY1114594T1 (el) 2016-10-05
RS51614B (sr) 2011-08-31
KR101191833B1 (ko) 2012-10-16
GEP20104960B (en) 2010-04-26
AU2005290984A1 (en) 2006-04-13
PT1793844E (pt) 2011-03-10
US20090081164A1 (en) 2009-03-26
KR20070073761A (ko) 2007-07-10
USRE43371E1 (en) 2012-05-08
WO2006038088A1 (en) 2006-04-13
IL182362A0 (en) 2007-07-24
CA2580448A1 (en) 2006-04-13
US7439227B2 (en) 2008-10-21
UA88484C2 (ru) 2009-10-26
EA200700725A1 (ru) 2007-10-26
NZ554412A (en) 2011-01-28
SG139750A1 (en) 2008-02-29
HRP20110169T1 (hr) 2011-04-30
US20060252675A1 (en) 2006-11-09
CN101056648A (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
TNSN07084A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2007100776A3 (en) Antimicrobial compositions and methods for locking catheters
WO2004045572A8 (en) Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
WO2005102392A3 (en) Combinations for treating hiv infection
WO2006034001A3 (en) Methods of treating hiv infection
EP2071030A3 (en) Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus
WO2006054182A3 (en) Phosphoindoles as hiv inhibitors
WO2005002522A3 (en) Compositions and methods for treating tissue ischemia
WO2007022219A3 (en) Dental composition comprising enzyme
DK1729732T3 (da) Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere
FR2875137B1 (fr) Dispositif de conditionnement de l'atmosphere par diffusion de substances aromatiques ou autres principes actifs volatils
DE60041198D1 (de) Antimikrobielle zusammensetzungen
JP2006527741A5 (pt)
ITMI20030972A1 (it) Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
FR2907682B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
WO2008144690A3 (en) Compositions and methods for enhancing active agent absorption
WO2005056581A3 (en) Peptide able to specifically bind a chemokine receptor and use thereof
Kim A Study on the period and place for" Zhulinqixian"'s gathering

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.